Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique

  title={Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique},
  author={Paulette Y. Mhawech-Fauceglia and S. Zhang and Luigi M. Terracciano and Guido Sauter and Arundhuti Chadhuri and F{\'a}bio Herrmann and Remedios B. Penetrante},
Aims:  To determine prostate‐specific membrane antigen (PSMA) expression in normal tissues and in 3161 benign and malignant tumours and subsequently to define its sensitivity and specificity in prostatic adenocarcinoma (PaC). 

Prostate‐specific membrane antigen expression in melanoma metastases

The aim of this study was to investigate the performance of PSMA immunohistochemistry on resected melanoma metastases to explore its use as a diagnostic imaging biomarker for melanoma.

Prostate‐specific membrane antigen for the surgical oncologist: interpreting expression beyond the prostate

The use of prostate‐specific membrane antigen (PSMA) radiotracer in positron emission tomography (PET) has been successfully incorporated into the clinical management of prostate cancer. However,

Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature

The finding of FH(PSA)1 in the bladder cancer neovasculature suggests that this molecule may promote tumor growth and may represent a potential new vascular target in this disease.

Prostate‐specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain

It is reported that the vascular expression of PSMA in the primary and secondary brain tumours globally associates with the malignant progression and poor outcome of the patients.

Comparative analysis of monoclonal antibodies against prostate‐specific membrane antigen (PSMA)

Prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is generally recognized as a diagnostic and therapeutic cancer antigen and a molecular address for

Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma

PSMA is underexpressed in advanced stage EAC, loss of PSMA expression can be considered as a prognostic marker in patients with EAC and loss ofPSMA expression in a subset of EAC cases could be due to epigenetic silencing.

Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy

Examination of expression of prostate-specific membrane antigen in neovasculature of gynecologic cancers showed PSMA expression in tumor vasculature was diffuse in majority of cases, rendering it a potential therapeutic vascular target.

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer

PSMA could be a new diagnostic and therapeutic alternative, particularly for triple-negative breast cancer, and appears to be a potential predictive and prognostic marker.



Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

It is concluded that PSMA overexpression is detected in high-grade PIN and is associated with a higher Gleason score of prostate cancer.

Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

These findings expand the possible therapeutic role of PSMA and establish it as a unique biomarker specifically produced and expressed by tumor-associated neovasculature but not produced or expressed by normal vessels.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

  • J. RossC. Sheehan B. Kallakury
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
This study demonstrates for the first time that overexpression of PSMA in primary PCa correlates with other adverse traditional prognostic factors and independently predicts disease outcome.

Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?

  • J. GalaS. Loric B. Tombal
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
Preliminary results suggest that a blood-borne PSMA mRNA PCR assay may be a useful tool to predict a poor outcome in TCC patients.

Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen

Identification of new biochemical markers for disease progression will provide important tools for diagnosis and monitoring and one such potential marker is prostate specific membrane antigen (PSMA).

Molecular expression of PSMA mRNA and protein in primary renal tumors

Since PSMA does not appear to be restricted to prostatic tissue, this novel biomarker may prove useful in the staging of renal cancer and in the search for the hematogenous spread of renal cells.

Expression analysis of δ‐catenin and prostate‐specific membrane antigen: Their potential as diagnostic markers for prostate cancer

The current approach to prostate cancer diagnosis has major limitations including the inability of prostate‐specific antigen (PSA) assays to accurately differentiate between prostate cancer and

Prostate-specific membrane antigen expression in normal and malignant human tissues.

The decrease in PSMA immunoreactivity noted in advanced prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation and the neoexpression of PSMA in endothelial cells of capillary beds in certain tumors may be related to tumor angiogenesis and suggests a potential mechanism for specific targeting of tumor neovasculature.

Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice.

An immunocytochemical method to localise prostate-specific antigen (PSA) in paraffin sections was used to establish the prostatic origin of both primary and metastatic tumours, finding 11 patients with neoplasms of the base and neck of the bladder that could not be categorised as prostatic or urothelial in origin by clinical and endoscopic assessment or by conventional histopathology.